Dupixent EOE denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent eoe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues Non-Formulary Denials for Dupixent (EoE)

Dupixent is a specialty biologic and, depending on the specific UHC plan benefit design, may sit on a non-preferred tier or be excluded from the formulary altogether. A non-formulary denial means the plan's drug list does not include the medication at a covered tier — but this is not the end of the road. UHC plans are generally required to offer a formulary exception process, and FDA-approved medications with a strong clinical rationale frequently succeed at exception.

## Why This Denial Is Appealable

For a condition like EoE, where Dupixent carries a specific FDA approval and may represent the only available biologic therapy, a non-formulary denial is particularly vulnerable to appeal. If no covered formulary alternative is clinically appropriate for this patient — either because alternatives lack the same indication or because the patient has tried and failed them — the plan must consider a formulary exception granting access at a covered cost-sharing tier.

## Federal Appeal Framework

• Formulary exception request: File this first, simultaneously with or before a formal internal appeal. Provide the prescriber's attestation that no covered formulary alternative is clinically appropriate.
• Internal appeal: If the exception is denied, file a formal internal appeal under ERISA §503 or the ACA §2719 framework within the deadline on the denial notice.
• External review: After exhausting internal appeal, request independent external review. The IRO will evaluate whether the plan's formulary exclusion as applied to this patient is consistent with generally accepted standards of care. File within approximately four months of the final internal denial (confirm exact date on your denial notice).
• Expedited track: Available if delay would seriously jeopardize health or ability to regain maximum function.

## Documentation to Gather

1. Diagnosis confirmation: Endoscopic biopsy pathology, gastroenterologist's diagnostic letter. 2. Formulary alternatives review: A prescriber letter explaining why each covered formulary alternative either lacks an EoE indication, is medically contraindicated for this patient, or was previously tried and failed — with dates and outcomes for each. 3. Clinical severity: Chart notes documenting disease burden, symptom frequency, impact on nutrition, and endoscopic or histologic findings. 4. FDA-label alignment: Statement that the patient meets the patient population described in Dupixent's FDA-approved labeling for EoE.

## Criteria-Mapping Structure

Obtain UHC's formulary exception policy and the plan's evidence of coverage document. List each requirement for a formulary exception verbatim. For each requirement, cite the chart note, lab, or prescriber statement that satisfies it. If UHC points to a specific covered alternative, address that alternative by name and explain — with documented clinical reasoning — why it is not appropriate for this patient. A structured, criterion-by-criterion response is far harder for a reviewer to deny than a general narrative letter.